Prescient Therapeutics takes cap raise to $9.8m to fast-track cancer treatment
Special Report: Prescient Therapeutics has raised $3m in a placement to sophisticated and professional investors following...
Special Report: Prescient Therapeutics has raised $3m in a placement to sophisticated and professional investors following...
Prescient Therapeutics has entered a critical stage where clinical data, regulatory support, and commercial potential...
Prescient Therapeutics has reached a key milestone in its clinical development program, initiating its first...
Stockhead’s Tylah Tully catches up with Prescient Therapeutics (ASX:PTX) CEO James McDonnell after the company hit a...
What is Relapsed or Refractory T-Cell Lymphoma? Why is it so difficult to treat? What...
Clinical stage biotech Prescient Therapeutics is developing new therapies for cancers of unmet need, aggressive...
The first patient has been dosed in Prescient Therapeutics Phase 2a clinical trial of PTX-100...
Cell and gene therapy is changing the game when it comes to cancer treatment and...
CAR-T therapy is leading the race as the holy grail to cure cancer but like...
Prescient’s work is being considered a game-changer in advancing CAR-T therapies for cancer treatment and...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.